Christine J. Guico-Pabia | Psychiatrist.com

Original Research

Assessing the Efficacy of Desvenlafaxine for Improving Functioning and Well-Being Outcome Measures in Patients With Major Depressive Disorder: A Pooled Analysis of 9 Double-Blind, Placebo-Controlled, 8-Week Clinical Trials

Original Research

Cytochrome P450 2D6 Phenoconversion Is Common in Patients Being Treated for Depression: Implications for Personalized Medicine

Original Research

Cytochrome P450 2D6 Phenotype Predicts Antidepressant Efficacy of Venlafaxine: A Secondary Analysis of 4 Studies in Major Depressive Disorder

Article

Short-Term Efficacy and Safety of Desvenlafaxine in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder

Article

An Analysis of Relapse Rates and Predictors of Relapse in 2 Randomized, Placebo-Controlled Trials of Desvenlafaxine for Major Depressive Disorder

In this article by McIntyre and colleagues, relapse rates and predictors of relapse were evaluated in 2 randomized, placebo-controlled trials of desvenlafaxine for major depressive disorder.

Article

Beyond Symptomatic Improvement: Assessing Real-World Outcomes in Patients With Major Depressive Disorder

The objective of this systematic review was to measure the negative impact that MDD has on quality of life, disability, and work, family, and overall psychosocial functioning. Available scales...

Article

A Post Hoc Analysis of the Effect of Weight on Efficacy in Depressed Patients Treated With Desvenlafaxine 50 mg/d and 100 mg/d

The authors of this article conducted a post hoc analysis of data from 8 short-term and 1 longer-term double-blind, placebo-controlled studies of patients with major depressive disorder treated with...

Article

Improving Quality of Depression Care Using Organized Systems of Care: A Review of the Literature

The authors of this article attempt to establish the need for a chronic disease management strategy for major depressive disorder, discuss the challenges involved in implementing guideline-level treatment, and...

Article

Incidence and Timing of Taper/Posttherapy-Emergent Adverse Events Following Discontinuation of Desvenlafaxine 50 mg/d in Patients With Major Depressive Disorder

Here, review results from a post hoc analysis that evaluated the tolerability of long-term desvenlafaxine for major depressive disorder at discontinuation using a taper regimen compared with abrupt discontinuation.Â